William Blair Starts Lyra Therapeutics (LYRA) at Outperform

May 26, 2020 6:10 AM EDT
Get Alerts LYRA Hot Sheet
Price: $9.28 +0.98%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 12 | New: 42
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

William Blair analyst Tim Lugo initiates coverage on Lyra Therapeutics (NASDAQ: LYRA) with an Outperform rating.

The analyst commented, "Lyra is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat (ENT) diseases. The company’s lead product, LYR-210, leverages its proprietary XTreo technology platform to provide sustained local delivery of small molecule therapies for the treatment of surgically naïve chronic rhinosinusitis (CRS) patients. The active ingredient in LYR-210 is mometasone furoate (MF), a corticosteroid that is the active ingredient in multiple FDA-approved therapies and widely used as a nasal spray for the treatment of CRS."

For an analyst ratings summary and ratings history on Lyra Therapeutics click here. For more ratings news on Lyra Therapeutics click here.

Shares of Lyra Therapeutics closed at $14.43 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

William Blair, FDA